CHMP recommends nine drugs in March

A total of 21 new drugs have been recommended for approval in 2023.

For subscribers

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Photo: Ida Marie Odgaard

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

For subscribers

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

New study says AstraZeneca drug rarely leads to RSV mutations

For subscribers

Bluebird Bio expects delay on FDA sickle cell drug application

For subscribers

WHO mulls over labeling obesity drugs as essential medicines
A request to consider a Novo Nordisk obesity drug as an essential medicine was submitted by three doctors and a scientist in the US.
For subscribers
Watchdog looking into Novo Nordisk sponsorship of patient group
The Danish drugmaker has until mid-April to produce materials related to a case concerning a sponsorship of a Danish patient organization.
For subscribers
J&J drops RSV vaccine after two competitors get closer to approval
Both Pfizer and GSK recently won the approval of an FDA panel for their respective vaccines, and Johnson & Johnson now bows out of the race to get a vaccine against the lung infection.
For subscribers
Lundbeck and ALK boost the Lundbeck Foundation's operating result
Though the foundation’s investment activities hemorrhaged DKK 2bn over 2022, fine performances by pharmaceutical companies Lundbeck and ALK help lift the operating profit.
For subscribers
AstraZeneca retires diabetes drug in the Nordics
The market for an 11-year-old diabetes treatment has disappeared as new treatments have come out.
For subscribers
Americans prevented from buying Ozempic in British Columbia
”We don’t want to become a supplier for the US market,” says health minister in British Columbia.
For subscribers
Ferring closes research institute, fires staff
An expansion program had just been completed for the San Diego-based research unit that is now shutting down.
For subscribers
Danish pension fund argues for capping Genmab CEO's pay
Once the bonus-issued stock wealth of a CEO hits a certain level, bonuses should stop, says AkademikerPension.
For subscribers
Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market
Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.
For subscribers
Zealand Pharma presents positive early-stage results for weight-loss candidate
The Danish biotech company is encouraged, although more testing will be needed ”to fully assess the clinical potential” of a new obesity treatment candidate.
For subscribers
Denmark: Violation of good manufacturing practice is source of contaminated antibiotic
The Danish Medicines Agency seeks to bring the matter to European inspectors to increase awareness of potential problems in the future.
For subscribers
Analyst: New Novo Nordisk data sets the bar high for diabetes pills
Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025.
For subscribers
Genmab promotes senior VP for strategy to executive management
Martine van Vugt, a veteran at Genmab, has risen through the ranks.
For subscribers
Novo Nordisk chair boasts competitive production advantage
The Danish drugmaker’s chair says the company’s production facilities makes it one to watch, and Novo Nordisk is only increasing its investments into expanding capacity in 2023.
For subscribers
Novo Nordisk enters collaboration with AI-driven drug discovery company
Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.
For subscribers
California moves forward with making biosimilar insulin
The state has entered a contract with generic drugmaker Civica to make insulin products that are interchangeable with those of Novo Nordisk, Sanofi, and Eli Lilly.
For subscribers
Indian generic drugmaker to launch Leo Pharma copycat drug in US
Generic drugmaker Glenmark has received 180-day generic drug exclusivity on one of Leo Pharma’s inventions.
For subscribers
Obesity drug hit makes Novo Nordisk more valuable than Nestle
The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.
For subscribers
Production at contaminated CMO continues – authorities deny further risks
The Danish Medicines Agency says shutting down the one production line specifically making the contaminated Dicillin is adequate, although the root cause is still unknown.
For subscribers
Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide
The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.
For subscribers